Elan Diagnostics, Inc. (“EDx”) and Transition Therapeutics Inc. Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer’s Disease

DUBLIN, Ireland & TORONTO--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer’s disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer’s disease. Each patient’s planned treatment period is approximately 18 months.
MORE ON THIS TOPIC